ArticleFrontiers in cardiovascular medicine2017
An Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice.
Article in Frontiers in cardiovascular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Impacts of pro-inflammatory cytokines variant on cardiometabolic profile and premature coronary artery disease: A systematic review and meta-analysis.Journal of cellular and molecular medicine · 2024Pooled it
- Therapeutic Applications of Immunobiologics in Autoimmune and Inflammatory Diseases.Pharmaceutics · 2026Review
- Network Pharmacology and Experimental Validation of the Anti-Inflammatory Effect of Modified Qianzheng Powder in Atherosclerosis.Combinatorial chemistry & high throughput screening · 2026Article
- Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study.Circulation. Genomic and precision medicine · 2025Review
- Application of therapeutical nanoparticles with neutrophil membrane camouflaging for inflammatory plaques targeting against atherosclerosis.Materials today. Bio · 2025Article
- IL-6 and Cardiovascular Risk: A Narrative Review.Current atherosclerosis reports · 2024Review
- Leucine-rich alpha-2-glycoprotein 1 affects bone destruction via IL-6 in mouse periodontitis model.Oral diseases · 2024Article
- Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases.Nature reviews. Rheumatology · 2024Review
- Blockade of IL-6 signaling alleviates atherosclerosis inNature cardiovascular research · 2023Article
- In Vitro Anti-Inflammatory and Vasculoprotective Effects of Red Cell Extract from the Black Sea UrchinNutrients · 2023Article
- Effect of Sphingomyelinase-Treated LDLs on HUVECs.Molecules (Basel, Switzerland) · 2023Article
- Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand?Reviews in cardiovascular medicine · 2023Review
- Interleukin-6 Predicts Carotid Plaque Severity, Vulnerability, and Progression.Circulation research · 2022Article
- Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-κB/IL-6 signaling pathway.Cellular and molecular life sciences : CMLS · 2022Article
- Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications.Cardiovascular drugs and therapy · 2022Review
- Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases.International journal of molecular sciences · 2022Review
- Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc).Frontiers in pharmacology · 2022Article
- Integrated pyroptosis measurement and metabolomics to elucidate the effect and mechanism of tangzhiqing on atherosclerosis.Frontiers in physiology · 2022Article
- From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?Cardiovascular research · 2021Article
- Filamin A Regulates Cardiovascular Remodeling.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IκBNS is a nuclear IκB protein which negatively regulates nuclear factor-κB activity. We demonstrated that IκBNS deficiency accelerates atherosclerosis in LDL receptor-deficient (LDLr
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.